Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol

HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom

(2016) Michael France et al.   ATHEROSCLEROSIS

Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study

(2016) Frederick J. Raal et al.   ATHEROSCLEROSIS

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry

(2016) Rodrigo Alonso et al.   Journal of Clinical Lipidology

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel

(2016) Raul D Santos et al.   Lancet Diabetes & Endocrinology

Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes

(2015) Gilbert R. Thompson et al.   ATHEROSCLEROSIS

Impact of LDL apheresis on aortic root atheroma in children with homozygous familial hypercholesterolemia

(2015) Bruno Lefort et al.   ATHEROSCLEROSIS

Managing homozygous familial hypercholesterolaemia from cradle to grave

(2015) Gilbert R. Thompson   ATHEROSCLEROSIS SUPPLEMENTS

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

(2014) M. Cuchel et al.   EUROPEAN HEART JOURNAL

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

(2012) Marina Cuchel et al.   LANCET

Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy

(2011) Frederick J. Raal et al.   CIRCULATION

Management of Familial Hypercholesterolemias in adult patients: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

(2011) Matthew K. Ito et al.   Journal of Clinical Lipidology

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

(2010) Frederick J Raal et al.   LANCET

A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia

(2007) A. David Marais et al.   ATHEROSCLEROSIS